Table 3.
Clinical and demographic parameters in both subgroup of lung cancer patients (dead patients or survivors).
| Survivor patients (N = 8) | Dead patients (N = 9) | p value | |
|---|---|---|---|
| Age, median | 72 | 64.5 | 0.12 |
| Male, n (%) | 7 (87.5) | 6 (66.7) | 0.31 |
| Cancer characteristics | |||
| Cancer treatment | |||
| Chemotherapy, n (%) | 3 (37.5 %) | 2 (22.2 %) | 0.70 |
| Staging | |||
| Metastatic disease, n (%) | 4 (50.0 %) | 7 (77.8 %) | 0.23 |
| Covid-19 characteristics | |||
| Covid-19 Treatment | |||
| Hydroxichloroquine + azytromicin, n (%) | 7 (87.5 %) | 1 (11.1 %) | 003 |
| Covid-19 symptoms | |||
| Fever, n (%) | 6 (75.0 %) | 6 (66.7 %) | 0.70 |
| Cough, n (%) | 8 (100 %) | 9 (100 %) | – |
| Severe infection, n (%) | 4 (50.0 %) | 7 (77.8 %) | 023 |
| Comorbidities | |||
| Hypertension, n (%) | 4 (50.0 %) | 6 (66.7 %) | 0.48 |
| COPD, n (%) | 5 (62.5 %) | 4 (44.4 %) | 0.45 |
| CKD, n (%) | 1 (12.5 %) | 0 (0.0 %) | 0.27 |
| Obesity, n (%) | 1 (12.5 %) | 2 (22. %) | 0.60 |
Abbreviations: COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease.